MARKET

NWBO

NWBO

Northwest Bio
OTCMQB
0.600
+0.002
+0.38%
Closed 15:59 03/30 EDT
OPEN
0.630
PREV CLOSE
0.598
HIGH
0.630
LOW
0.595
VOLUME
281.58K
TURNOVER
171.02K
52 WEEK HIGH
2.150
52 WEEK LOW
0.386
MARKET CAP
643.73M
P/E (TTM)
-5.8423
1D
5D
1M
3M
1Y
5Y
Northwest Biotherapeutics, Advent get license for cell therapy facility in UK
Seeking Alpha · 03/21 10:51
BRIEF-Northwest Biotherapeutics And Advent Bioservices Announce Receipt Of License For Commercial Manufacturing At Sawston, U.K. Facility
Reuters · 03/20 23:47
BRIEF-Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB
Reuters · 03/11 23:06
Northwest Bio in $11M loan agreement with Streeterville Capital
Seeking Alpha · 03/09 11:49
Northwest Bio: No BLA Date, And A Major Lawsuit
Seeking Alpha · 02/12 11:18
Cancer drug company accuses US market makers of stock spoofing
A cancer-focused biotechnology company has sued eight of the US’s largest market-making traders including Citadel Securities, Susquehanna and Virtu, alleging that they deliberately drove down its share price by placing sell orders they had no intention of ...
Financial Times · 12/01/2022 18:17
Market Chatter: Northwest Biotherapeutics Sues Citadel Securities, Other Market Market Makers for Alleged Stock Price Manipulation
Market Chatter: Northwest Biotherapeutics Sues Citadel Securities, Other Market Market Makers for Alleged Stock Price Manipulation
MT Newswires · 12/01/2022 10:26
Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma
Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported that in its Phase III clinical trial both median survival and the "long tail" of extended su...
PR Newswire · 11/17/2022 17:36
More
About NWBO
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company's lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company's platform technology, DCVax, uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.

Webull offers kinds of Northwest Biotherapeutics, Inc stock information, including OTCMQB:NWBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NWBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NWBO stock methods without spending real money on the virtual paper trading platform.